Trial Profile

A clinical trial to demonstrate BJT-778 proof-of-concept in CHBV patients

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 21 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brelovitug (Primary)
Indications Hepatitis B; Hepatitis D
Focus First in man; Proof of concept; Therapeutic Use

Most Recent Events

15 Nov 2024 According to a Bluejay Therapeutics media release, Longe-term, 48-week data across all dose arms are expected to be shared in the second half of 2025.
15 Nov 2024 Results presented in the Bluejay Therapeutics Media Release.
16 Oct 2024 According to a Bluejay Therapeutics media release, data from this study will be presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting, taking place November 15-19, in San Diego, California.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com